December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Intravitreal Triamcinolone for Diabetic Macular Edema: A Clinical andFluorescein Angiographic Study
Author Affiliations & Notes
  • SJ Bakri
    Lions Eye Institute Albany Medical College Albany NY
  • PM Beer
    The Retina Office Slingerlands NY
  • Footnotes
    Commercial Relationships   S.J. Bakri, None; P.M. Beer, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3458. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SJ Bakri, PM Beer; Intravitreal Triamcinolone for Diabetic Macular Edema: A Clinical andFluorescein Angiographic Study . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3458.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To report the outcome of treatment of persistent diabetic macular edema with an intravitreal injection of triamcinolone acetonide. Methods: Retrospective interventional non-comparative case series. Nineteen eyes of 16 patients with diabetic macular edema persistent after focal or grid laser photocoagulation received a single 4mg intravitreal triamcinolone injection. Outcome measures were Snellen visual acuity, Goldmann intraocular pressure and fluorescein angiography. Results: Four eyes (21.1%) showed a marked improvement, 10 (52.6%) showed a mild improvement, and 5 (26.3%) showed no change of macular edema on fluorescein angiography. No patients had worsening of their macular edema. Visual acuity improved by 1 or more lines in 13 eyes (68.4%), by 2 or more lines in 5 eyes (26.3%), by 3 or more lines in 2 eyes (10.5%) and by 4 lines in 1 eye (5.3%). Acuity remained unchanged in 5 eyes (26.3%), and deteriorated by 1 line in 1 eye. An intraocular pressure elevation of 10mmHg or greater occurred in 2 eyes (10.5%), and was successfully treated by topical medication. The triamcinolone was well-tolerated and there were no other ocular complications. Conclusion: Intravitreal triamcinolone resulted in angiographic improvement of macular edema in 74% of 19 eyes, with visual improvement in 68.4%, and was well-tolerated. A significant intraocular pressure rise occurring in 10.5% of eyes responded to topical medication in all cases. Intravitreal triamcinolone has potential as a new modality in the treatment of diabetic macular edema, and would be worth investigating in a randomized prospective clinical trial.  


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.